15 research outputs found
Among those who attended Sero 6, proportions of men (n = 3,131) and women (n = 4,877) using different HCT services.
<p>Among those who attended Sero 6, proportions of men (n = 3,131) and women (n = 4,877) using different HCT services.</p
By HIV status: number of times individuals reported using VCT at an earlier sero-survey round, versus number of times VCT was actually used at the earlier round.
<p>By HIV status: number of times individuals reported using VCT at an earlier sero-survey round, versus number of times VCT was actually used at the earlier round.</p
Crude and adjusted odds ratios for clinical and behavioural factors associated with VCT uptake at Sero-6.
*<p>p≤0.05,</p>¶<p>p≤0.1.</p><p>Adjusted for all socio-demographic, clinical & behavioural factors associated with VCT use in univariable analyses (p≤0.10) and remaining significant in multivariable analyses.</p><p>α Reported or documented (at an earlier sero-survey round) previous HCT use.</p><p>Δ Spouse’s HIV status & VCT use at current sero-survey round.</p><p>Ω Frequency of condom use in last 12 months considering three most recent partners.</p
Characteristics of individuals attending both Sero-5 and Sero-6 and factors associated with repeat use of VCT at each round<sup>#.</sup>
<p>#Characteristics and behavioural variables are those reported at Sero-6, unless otherwise stated.</p>*<p>p≤0.05,</p>¶<p>p≤0.1.</p><p>Δ Spouse HIV status and VCT use at Sero-6.</p><p>Ω Frequency of condom use in last 12 months considering three most recent partners.</p
Number of times HCT was ever used (i.e. at sero-surveys and/or elsewhere) by the end of each sero-survey round by HIV status.
<p>Panel A) men; panel B) women. (NB: HIV status reflects status at the sero-survey round in question, rather than at any earlier test).</p
Univariable analysis of factors most strongly associated with VCT uptake at sero-surveys 4, 5 and 6<sup>¤.</sup>
¤<p>Figures for VCT uptake at Seros 4 and 5 reflect an update on previous figures presented by Wringe <i>et al</i><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062212#pone.0062212-Wringe1" target="_blank">[13]</a> and Isingo <i>et al</i><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062212#pone.0062212-Isingo1" target="_blank">[14]</a>. The figures are provided here for context.</p>*<p>p≤0.05,</p>¶<p>p≤0.1.</p><p>α Reported or documented (at an earlier sero-survey round) previous HCT use.</p><p>Δ Spouse’s HIV status & VCT use at current sero-survey round.</p
Additional file 1: of Uptake of services for prevention of mother-to-child transmission of HIV in a community cohort in rural Tanzania from 2005 to 2012
Adjusted coverage estimates for the proportion of HIV-positive pregnant women who a) accessed ANC, b) enrolled in care at PMTCT/CTC, and c) accessed ARVs, in each pregnancy by year. (XLSX 13 kb
Data sources, data availability and definitions—COVID-19 cases.
Data sources, data availability and definitions—COVID-19 cases.</p
Data collection template all cause deaths.
Where appropriate for a study protocol, the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER, http://gather-statement.org/) have been considered in the preparation of this article [45]. (XLSX)</p
Data sources, data availability and definitions—COVID-19 deaths.
Data sources, data availability and definitions—COVID-19 deaths.</p